Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity

References

• Andrade RJ, López-Ortega S, López-Vega MC, Robles M, Cueto I, Lucena MI. 2008. Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Rev Clin Pharmacol. 1(2):261–276.
   PubMedGoogle Scholar
• Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. 2002. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol. 188(1–2):111–123.
   PubMed Web of Science ®Google Scholar
• Authors not listed. 2018. Ulipristal acetate (Esmya): restrictions on use. Drug Ther Bull. 56:127.
   PubMedGoogle Scholar
• Authors not listed. 2019. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 70:1222–1261.
   PubMed Web of Science ®Google Scholar
• Authors not listed. 2020a. EMA recommends restricting use of ulipristal: risk of liver injury. React Wkly. 1832:5–5.
   Google Scholar
• Authors not listed. 2020b. EMA suspends licence for ulipristal acetate for uterine fibroids. Drug Ther Bull. 58:70.
   PubMedGoogle Scholar
• Batur P, Kransdorf LN, Casey PM. 2016. Emergency contraception. Mayo Clin Proc. 91(6):802–807.
   PubMed Web of Science ®Google Scholar
• Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. 2003. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 68(10–13):1013–1017.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Björnsson E. 2010. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 138(7):2246–2259.
   PubMed Web of Science ®Google Scholar
• Chen W, Xiao Y, Chen J, Liu J, Shao J, Li T, Zhu Y, Ma J, Gao Y, Wang J, et al. 2017. Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite). Sci Rep. 7(1):17190–17190.
   PubMed Web of Science ®Google Scholar
• Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, Nguyen H, Emerson SU, Purcell RH, et al. 2011. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 141(5):1665–1672.e1661-1669.
   PubMed Web of Science ®Google Scholar
• Del Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, Raimondo D, Paradisi R, Seracchioli R. 2020. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. Gynecol Endocrinol. 36(5):445–447.
   PubMed Web of Science ®Google Scholar
• Donnez J. 2018. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 110(4):593–595.
   PubMed Web of Science ®Google Scholar
• Donnez J, Arriagada P, Marciniak M, Larrey D. 2018. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 17(12):1225–1232.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, et al. 2012. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 366(5):409–420.
   PubMed Web of Science ®Google Scholar
• Ekanem E, Talaulikar V. 2021. Medical therapy for fibroids: what next for ulipristal acetate? Adv Ther. 38(1):137–148.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2014. Esmya: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002041/WC500124085.pdf. London: European Medicines Agency.
   Google Scholar
• European Medicines Agency 2018a. Esmya Article-20 procedure – PRAC assessment report. London: European Medicines Agency. https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-assessment-report_en.pdf.
   Google Scholar
• European Medicines Agency. 2018b. PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids. London: European Medicine Agency. https://www.ema.europa.eu/en/documents/referral/esmya-article-20-procedure-prac-recommends-new-measures-minimise-risk-rare-serious-liver-injury_en.pdf.
   Google Scholar
• European Medicines Agency. 2020a. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. London: European Medicines Agency. https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-review-started_en.pdf.
   Google Scholar
• European Medicines Agency. 2020b. Ulipristal acetate 5mg. Amsterdam: European Medicines Agency. https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-chmp-scientific-conclusions-prac_en.pdf.
   Google Scholar
• European Medicines Agency. 2021. Ulipristal acetate 5mg. Amsterdam: European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products.
   Google Scholar
• Ferrero S, Vellone VG, Barra F. 2018. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 14(1):107–116.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. 2010. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 52(2):730–742.
   PubMedGoogle Scholar
• Funke K, Rockey DC. 2019. Cholestatic drug-induced liver injury caused by mifepristone. Hepatology. 69(6):2704–2706.
   PubMed Web of Science ®Google Scholar
• Gatti M, Poluzzi E, De Ponti F, Raschi E. 2020. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 43(12):1277–1285.
   PubMed Web of Science ®Google Scholar
• Ghonim M, Magdy R, Sabbour M, Ghonim M, Nabhan A. 2019. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids. Int J Gynaecol Obstet. 146(2):141–148.
   PubMed Web of Science ®Google Scholar
• Heikinheimo O. 1990. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans. Acta Obstet Gynecol Scand. 69(4):357–358.
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lähteenmäki P. 1987. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem. 26(2):279–284.
   PubMedGoogle Scholar
• Jang GR, Benet LZ. 1997. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm. 25(6):647–672.
   PubMedGoogle Scholar
• Kaplowitz N. 2013. Chapter 1 - drug-induced liver injury: introduction and overview. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Boston: Academic Press; p. 3–14.
   Google Scholar
• Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. 2008. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 47(6):2003–2009.
   PubMed Web of Science ®Google Scholar
• Larner JM, Reel JR, Blye RP. 2000. Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration. Hum Reprod. 15(5):1100–1106.
   PubMed Web of Science ®Google Scholar
• Larrey D, Meunier L, Valla D, Hillaire S, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C. 2020. Drug induced liver injury and vascular liver disease. Clin Res Hepatol Gastroenterol. 44(4):471–479.
   PubMed Web of Science ®Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. 2008. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 111(5):1129–1136.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Cottu PH, Lehr M, Dick E, Shearer T, Rencher W, Bexon AS, Campone M, Varga A, Italiano A. 2020. Onapristone extended release: safety evaluation from phase I-II studies with an emphasis on hepatotoxicity. Drug Saf. 43(10):1045–1055.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Hollenberg PF. 2009. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. J Pharmacol Exp Ther. 329(1):26–37.
   PubMed Web of Science ®Google Scholar
• Melis GB, Piras B, Marotto MF, Orru MM, Maricosu G, Pilloni M, Guerriero S, Angiolucci M, Lello S, Paoletti AM. 2012. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma a treatment. Expert Opin Drug Metab Toxicol. 8(7):901–908.
   PubMed Web of Science ®Google Scholar
• Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, Dominique HB. 2020. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 44(3):e45–e49.
   PubMed Web of Science ®Google Scholar
• Middelkoop M-A, Bet PM, Drenth JPH, Huirne JAF, Hehenkamp WJK. 2021. Risk-efficacy balance of ulipristal acetate compared to surgical alternatives. Br J Clin Pharmacol. DOI:https://doi.org/10.1111/bcp.14708.
   PubMed Web of Science ®Google Scholar
• Mozzanega B. 2021. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. J Hepatol. 74(3):750–751.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. 2012. LiverTox: clinical and research information on drug-induced liver injury. [Updated 2019 May 4]. https://www.ncbi.nlm.nih.gov/books/NBK548392/.
   Google Scholar
• Nooredinvand HA, Connell DW, Asgheddi M, Abdullah M, O'Donoghue M, Campbell L, Wickremasinghe MI, Lalvani A, Kon OM, Khan SA. 2015. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol. 21(29):8920–8926.
   PubMed Web of Science ®Google Scholar
• Pohl O, Kendrick J, Gotteland J-P. 2013. Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women. J Bioequivalence Bioavailab. 5:177–184.
   Google Scholar
• Pohl O, Osterloh I, Gotteland JP. 2013a. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 38(6):512–517.
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Gotteland JP. 2013b. Ulipristal acetate – safety and pharmacokinetics following multiple doses of 10-50 mg per day. J Clin Pharm Ther. 38(4):314–320.
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Lecomte V, Gotteland JP. 2013. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 51(1):26–33.
   PubMed Web of Science ®Google Scholar
• Pohl O, Zobrist RH, Gotteland JP. 2015. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 22(4):476–483.
   PubMed Web of Science ®Google Scholar
• Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg H-R, De Wilde RL, Wallwiener M. 2018. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018:6124628.
   PubMed Web of Science ®Google Scholar
• Raschi E, De Ponti PF. 2019. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin-dependent kinase 4/6 inhibitors. Front Pharmacol. 10:1235.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S. 1999. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 35(2):214–218.
   PubMed Web of Science ®Google Scholar
• Roth RA, Ganey PE. 2010. Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one? J Pharmacol Exp Ther. 332(3):692–697.
   PubMed Web of Science ®Google Scholar
• Shah I, Putnam T, Daugherty E, Vyas N, Chuang KY. 2019. Mifepristone: an uncommon cause of drug-induced liver injury. Gastroenterology Res. 12(3):181–184.
   PubMed Web of Science ®Google Scholar
• Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S. 2020. The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor. J Clin Endocrinol Metab. 105(3):716–734.
   PubMed Web of Science ®Google Scholar
• Spitz IM. 2010. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 82(5):442–452.
   PubMed Web of Science ®Google Scholar
• Stewart EA. 2001. Uterine fibroids. Lancet. 357(9252):293–298.
   PubMed Web of Science ®Google Scholar
• Ura B, Monasta L, De Spelorzi YCC, Arrigoni G, Franchin C, Biffi S, Aloisio M, Gaita B, Licastro D, Athanasakis E, et al. 2021. Proteins involved in oxidative stress in leiomyoma tissues treated with ulipristal acetate. Mol Med Rep. 23(1):1.
   Web of Science ®Google Scholar
• Xiao Y, Zhu Y, Yu S, Yan C, Ho RJ, Liu J, Li T, Wang J, Wan L, Yang X, et al. 2016. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol Mech Methods. 26(1):36–45.
   PubMed Web of Science ®Google Scholar
• Yoon EL, Yuk JS. 2021. Use of ulipristal acetate and risk of liver disease: a nationwide cohort study. J Clin Endocrinol Metab. DOI:https://doi.org/10.1210/clinem/dgab081.
   Google Scholar
• Zimmerman HJ. 1993. Hepatotoxicity. Dis Mon. 39(10):675–787.
   PubMed Web of Science ®Google Scholar